Stroke Study Reveals Key Target For Improving Treatment
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
Bowel Prep Oral Sodium Phosphate Equal To Fasting Before Capsule Endoscopy For Obscure GI Bleeding
According to a new study from researchers in France, bowel preparation with oral sodium phosphate for capsule endoscopy in patients with obscure gastrointestinal (GI) bleeding is no better at cleansing the small bowel than the standard method of preparation, which is an eight-hour fast before the procedure.
Poor Children More Likely To Develop Diabetes As Adults
Diabetes strikes harder at those who were poor as children, according to a new study that spans more than three decades. Participants who were disadvantaged in youth were more likely to develop diabetes than better-off peers were during the 34-year study timeframe.
Forest Laboratories Announces Positive Results From Phase III Clinical Studies Of Ceftaroline For The Treatment Of Complicated Skin And Skin Structure
Forest Laboratories, Inc. (NYSE: FRX) announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI).
US WorldMeds Completes Phase III Trial Of Lofexidine For Treatment Of Opiate Withdrawal Symptoms
US WorldMeds, a Kentucky-based specialty pharmaceutical company, announced that a recently completed Phase III clinical trial investigating the use of lofexidine hydrochloride (Lofexidine) for the treatment of opiate withdrawal symptoms in patients undergoing opiate detoxification has shown that.
Long-Term Safety Data On Lialda TM mesalamine For Patients With Ulcerative Colitis Published In Leading GI Journal
Shire Limited (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda(TM) (mesalamine).
Two-Year Clinical Trial Findings Show Significant And Persistent Reduction In Blood Pressure With CVRx R Rheos R Hypertension Therapy
The first available two-year data from the European clinical trial evaluating the Rheos Hypertension (HT) System were presented at Hypertension Berlin 2008. Developed by U.S.-based CVRx, Inc., the Rheos HT System is the only implantable medical device designed to control hypertension, or high blood pressure.
New Technology May Prevent Vitamin B12 Deficient Seniors And Vegetarians From Needing Injections
Pharmaceutical scientists from across the globe present health discoveries at the American Association of Pharmaceutical Scientists' National Biotechnology ConferenceFor those patients who receive the nearly 40 million intramuscular injections per year to treat their B12 deficiency, a new oral option may soon exist.
Epratuzumab Reduced Disease Activity And Steroid Use In Patients With Moderate And Severe Flaring SLE
UCB has announced that data presented recently show that epratuzumab treatment demonstrated clinically meaningful improvements in moderate and severe flaring systemic lupus erythematosus (SLE) patients. The data were from the first placebo-controlled studies using epratuzumab in SLE patients and were presented at the annual European Congress of Rheumatology (EULAR).
Long-Term Safety Data On Lialda Published In Leading GI Journal
Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™ (mesalamine).